Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01881919
Other study ID # MEEC12-019
Secondary ID
Status Completed
Phase Phase 0
First received June 7, 2013
Last updated March 20, 2015
Start date February 2013
Est. completion date November 2014

Study information

Verified date March 2015
Source University of Leeds
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study was to test the effect of chronic consumption of Quercetin 500 mg tablets on blood uric acid and other biomarkers in adult males.


Description:

The main goal of the research is to determine the long term effects of daily supplementation of quercetin, a compound naturally and normally present in food, on the chemical composition (uric acid ii and glucose) of blood and urine and on blood pressure, of healthy males.

Six of the volunteers will collect urine after consuming a standard meal made from fresh onion and after quercetin supplement intake, in the same way, with 3 days washout before each. The urine collected here will be analysed to check that the supplement is equivalent to the food. Stage 2 will only be conducted with supplement and placebo.

Healthy male volunteers with higher (than average) blood uric acid will be selected and will be asked to consume a standard supplement/placebo added to their own diet for 4 weeks per phase. Two arms are separated by 4 weeks resting period: quercetin supplement and placebo. Blood and urine samples will be taken every other week to detect any changes of uric acid and other biomarkers.

----- i) Quercetin is found in a variety of foods including apples, berries, brassica vegetables, capers, grapes, onions, shallots, tea, and tomatoes, as well as many seeds, nuts, flowers, barks, and leaves.

ii) Uric acid, a compound found in both in the human body and urine, is produced by the breakdown of purines, which are nitrogen-containing compounds in substances such as nucleic acids (DNA). They enter the circulation from digestion of certain foods, drinks (alcoholic beverages like beer and wine) or from normal breakdown and turnover of cells in the body. Most uric acid is removed by the kidneys and disposed of in the urine; the remainder is excreted in the stool.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date November 2014
Est. primary completion date April 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 19 Years to 65 Years
Eligibility Inclusion Criteria:

- Written informed consent

- Plasma Uric Acid > 300 micro Mole/L

- Generally Healthy

Exclusion Criteria:

- Body Mass Index (BMI) = 30 kg/m² or <18.5 kg/m²

- Unable or unwilling to comply with the protocol, or likely to leave the study before its completion.

- Who would undertake important change in physical exercise or vigorous sport competitions during the study period.

- regularly drink more than 3 units of alcohol every day

- smokers

- have history of treated hyperuricemia, gout and/ or kidney stone

- have intestinal disorders

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Intervention

Dietary Supplement:
Treatment
Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
Control
Address: Fagron GmbH&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680

Locations

Country Name City State
United Kingdom School of Food Science and Nutrition Leeds West Yorkshire

Sponsors (1)

Lead Sponsor Collaborator
University of Leeds

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Urinary excretion of quercetin To monitor the compliance of subject. 24 h urine will be collected on day 14 and 28 of each arm and volume is recorded No
Other Subject Body Weight To monitor the compliance of subject. weight is measured on day 1 and 29 of each arm No
Other Subject Height To monitor the compliance of subject. Height is measured on day 1 and 29 of each arm No
Other Life style maintenance To monitor the compliance of subject. Recall Questionnaires about the past 28 days are required on day 1 and 29 of each arm. No
Other Primary health assessment To set baseline for maintaining lifestyle and routine medicine for the study. Recall Questionnaires about history of certain disease, routine medication / supplements, allergies and exercise/diet practice at enrollment No
Primary Risk of getting hyperuricemia assessed by the measure of plasma uric acid. The change of plasma uric acid level from day 1 on day 15 and day 29 of each arm. Fasting blood samples are taken on day 1, day 15 and day 29 of each arm No
Secondary Kidney excretion of uric acid: urinary uric acid level Difference in 24-h urinary uric acid level at 14 days and 28 days between arms 24 h urine samples are collected on day 14 and 28 of each arm and volume is recorded No
Secondary Blood pressure To monitor the compliance of subject. Blood pressure is measured on day 1 and 29 of each arm No
Secondary Blood glucose The change of plasma glucose level from the baseline at day 15 and day 29 of each arm. Fasted blood samples are collected on day 1, 15, 29 of each arm No
Secondary Metabolomic and metabonomic profiling of blood plasma 1H NMR (proton nuclear magnetic resonance ) Fasting blood samples are taken on day 1, day 15 and day 29 of each arm No
See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4